Slide 1: Starpharma Highlights of FY2016 Presentation
For personal use only Starpharma Highlights of FY2016 Presentation Melbourne, Australia; 30 August 2016: Starpharma Holdings Ltd (ASX:SPL, OTCQX: SPHRY) advises a brief audio interview and presentation with Chief Executive Officer Dr Jackie Fairley will be broadcast today by the Finance News Network
Slide 2: Media and company contacts; forward-looking statements
docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast,
Slide 3: Starpharma FY2016 Highlights
Dr. Jackie Fairley CEO For personal use only STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY Financial News Network Starpharma FY2016 Highlights 30 Aug 2016
Slide 4: Forward Looking Statements
For personal use only This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targe
Slide 5: A global leader in dendrimer nanoparticles
A global leader in dendrimer nanoparticles Starpharma’s portfolio - internal programs and commercial partnerships with leading companies For personal use only Starpharma’s Dendrimer Platform ~120 granted patents VivaGel® Portfolio DEP™ Drug Delivery Agrochemicals VivaGel® BV Internal Partnered Prios
Slide 6: Important regulatory and commercial milestones for VivaGel Portfolio
Important regulatory and commercial milestones for VivaGel® Portfolio For personal use only 4
Slide 7: Rapidly building momentum for DEP programs
Rapidly building momentum for DEP™ programs For personal use only 5
Slide 8: Adama Licenses Priostar for novel 2,4-D products
Adama Licenses Priostar® for novel 2,4-D products For personal use only 6
Slide 9: Starpharma Holdings – Key Financials
Starpharma Holdings – Key Financials Strong Financial Position For personal use only Key Financial Highlights FY2016: FY 2016 FY 2015 Key Financial Data AUD $M AUD $M • Total revenue and other income $4.6M (+173% - includes the first US$2M DEP™ AZ milestone) Total revenue & other income 4.6 1.7 • Ca
Slide 10: Operational Highlights
Operational Highlights VivaGel® Portfolio For personal use only • EU marketing approval for VivaGel® BV • Licensing deal with Aspen for VivaGel® BV (Australia and NZ) • Phase 3 clinical trials of VivaGel® BV for the prevention of recurrent BV >90% enrolled • License signed for the VivaGel® condom in
Slide 11: Development & Expansion of AstraZeneca partnership
Development & Expansion of AstraZeneca partnership “SPL estimates that each For personal use only product successfully commercialised under this agreement could be worth around US$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentiall
Slide 12: Outlook
Outlook DEP™ Drug Delivery For personal use only VivaGel® Portfolio Priostar® Agrochemicals • Further regulatory approvals for VivaGel® BV for Treatment & • Completion of DEP™ docetaxel • Progress with Adama 2,4-D Symptomatic Relief Phase 1 clinical trial and Priostar® license commencement of Phase